All the news Showing 10 of 56 articles from: Genotype 1bGet an RSS feed of these articles Show All news infohep newsEditors' picks from other sources Merck interferon-free combination shows high hepatitis C cure rate in early study Keith Alcorn / 05 November 2013 A two-drug combination of direct-acting antivirals developed by Merck achieved very high cure rates, with and without ribavirin, in patients with genotype 1 hepatitis C infection in a small study presented on Sunday ... Older people respond equally well to telaprevir triple therapy for hepatitis C Liz Highleyman / 24 October 2013 Interferon-based therapy with telaprevir (Incivo or Incivek) produced a similar cure rate with no notable increase in side-effects or treatment discontinuations for genotype 1 chronic hepatitis C patients over the age of 60, ... Faldaprevir demonstrates good early response in genotype 1 HIV/HCV co-infection Liz Highleyman / 22 October 2013 The HCV protease inhibitor faldaprevir added to pegylated interferon and ribavirin increased the likelihood that HIV/HCV co-infected people would achieve a sustained virological response at four weeks after completing treatment, according to a ... Simeprevir with interferon effective in genotype 4 HCV infection and for HIV/HCV co-infected people with genotype 1 hepatitis C Liz Highleyman / 21 October 2013 Adding the direct-acting hepatitis C drug simeprevir to pegylated interferon and ribavirin produced high response rates for HIV-positive people co-infected with HCV genotype 1, researchers reported at the 14th European AIDS ... Simeprevir boosts response to interferon-based hepatitis C therapy for prior relapsers Liz Highleyman / 03 June 2013 Adding the HCV protease inhibitor simeprevir (formerly TMC435) to pegylated interferon and ribavirin cured 79% of prior relapsers, and most were eligible to complete treatment after three months, according to ... ACH-3102 and sovaprevir show potent activity, high barrier to resistance in early studies Keith Alcorn / 14 May 2013 Achillion Pharmaceuticals' second-generation NS5A inhibitor ACH-3102 demonstrated potent activity against genotype 1a and 1b hepatitis C virus and can be safely co-administered with the company's investigational protease inhibitor sovaprevir (formerly ACH-1625), according to studies presented ... Vaniprevir boosts interferon/ribavirin response rate for prior non-responders with cirrhosis Liz Highleyman / 13 May 2013 The next-generation HCV protease inhibitor vaniprevir (MK-7009) increased post-treatment sustained response rates for previously treated genotype 1 chronic hepatitis C patients with liver cirrhosis when added to pegylated interferon plus ribavirin, researchers reported at ... Sofosbuvir + interferon/ribavirin cures 90% of people with hard-to-treat hepatitis C genotypes Liz Highleyman / 04 May 2013 Adding the second-generation HCV polymerase inhibitor sofosbuvir (formerly GS-7977) to pegylated interferon plus ribavirin led to a sustained response rate of 89% for treatment-naive patients with HCV genotype 1 in the NEUTRINO study, ... Second-generation protease inhibitor faldaprevir cures up to 80% of hepatitis C Keith Alcorn / 01 May 2013 A second-generation hepatitis C protease inhibitor, faldaprevir, cured up to 80% of previously untreated people with genotype 1 hepatitis C virus (HCV) infection when combined with pegylated interferon and ribavirin, Professor Peter Ferenci ... Second-generation HCV protease inhibitor simeprevir pushes triple therapy cure rate up to 80% Keith Alcorn / 01 May 2013 A second-generation hepatitis C protease inhibitor, simeprevir, cured around 80% of previously untreated people with genotype 1 hepatitis C virus (HCV) infection when combined with pegylated interferon and ribavirin, Professor Michael Manns of ... ← Prev1...23456Next → Other pages in this section Latest news All the news Hepatitis A Hepatitis B Hepatitis C Hepatitis D Hepatitis E Coronavirus NAFLD Treatment for hepatocellular carcinoma Transmission, epidemiology and prevention Health services, policy and advocacy Social issues Conference news Email bulletin archive